Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Epigenic Therapeutics Raises $20 Million in Angel and Pre-A Rounds for Epigenetic Drugs

publication date: Aug 8, 2022

Shanghai Epigenic Therapeutics raised $20 million in Angel and Pre-A fundings to develop new therapies by using gene editing technology to regulate the epigenetic genome. Epigenetic changes do not change the DNA sequence, but they can change how an individual’s DNA sequence is read. Epigenic Therapeutics has developed a proprietary technology platform using artificial intelligence algorithms to obtain an optimized CRISPR-Cas component that regulates expression of target gene(s) without changing DNA. Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital invested in the Pre-A funding while Angel investor FountainBridge Capital also participated. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China